Nyrada Inc – Brain Injury Program GLP Studies Further Update #2

Highlights:
•Additional study provided further data to support safety and tolerability of Nyrada’s lead Brain Injury drug candidate.
•Rat CNS testing satisfactorily completed under Good Laboratory Practice (GLP) conditions for NYR-BI03.
•Nyrada will continue to report on remaining GLP study results and remains on track to commence first in-human Phase I clinical trial for NYR-BI03 in late CY2024.